Milmiga (Liraglutide)

Liraglutide, the active ingredient in Milmiga, is a GLP‑1 receptor agonist presented as an injectable solution for subcutaneous use. It is indicated for improving blood glucose control in type 2 diabetes and for weight management in obesity. GNH USA supplies Milmiga as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Liraglutide acts on the GLP‑1 pathway to manage metabolic disorders. - Type 2 diabetes mellitus: improves glycaemic control by enhancing insulin secretion and reducing glucagon. - Obesity: promotes weight loss through appetite suppression and delayed gastric emptying. - Cardiovascular risk reduction: lowers major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease.

Liraglutide may cause a range of adverse reactions.

Common Side Effects: - Nausea: transient, often diminishes with continued therapy. - Diarrhoea: mild to moderate, may improve over time. - Constipation: occasional, manageable with diet. - Decreased appetite: contributes to weight loss.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Gallbladder disease: including cholelithiasis. - Severe hypoglycaemia: especially when combined with insulin or sulfonylureas. - Renal impairment: acute kidney injury in susceptible patients. - Thyroid C‑cell tumours: risk observed in rodent studies, monitor for neck masses.

Before initiating Milmiga, consider the following safety measures. - Renal function: assess baseline and monitor periodically. - Pancreatitis risk: discontinue if signs of pancreatitis appear. - Thyroid C‑cell tumours: avoid in patients with personal or family history of medullary thyroid carcinoma. - Pregnancy and lactation: use only if potential benefit outweighs risk. - Drug interactions: review concomitant insulin or sulfonylureas to prevent hypoglycaemia. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Liraglutide can interact with several medication classes.

Major Interactions (Avoid): - Insulin: may cause severe hypoglycaemia. - Sulfonylureas: increased risk of hypoglycaemia. - Medications that markedly slow gastric emptying: may exacerbate gastrointestinal effects.

Moderate Interactions (Monitor Closely):\n- Beta‑blockers: can mask hypoglycaemia symptoms. - Diuretics: may affect fluid balance and renal function.